Hunter Syndrome Treatment Market Size, Share, Growth Analysis, By Treatment(Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT)), By Region(North America, Europe) - Industry Forecast 2024-2031

Hunter Syndrome Treatment Market Competitive Landscape

To understand the competitive landscape, we are analyzing key Hunter Syndrome Treatment Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Hunter Syndrome Treatment Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

• for the development of such novel therapies are anticipated to be two major factors driving the market growth in the near future. For instance, in June 2019, Denali Therapeutics Inc. received FDA’s Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation for its pipeline drug candidate DNL310, which is being evaluated for the treatment of the disease.
•  Initiatives undertaken by various organizations for creating awareness regarding the disease diagnosis and its treatment is expected to support market growth over the forecast timeframe. For instance, in May 2018, Shire Plc. in collaboration with the National MPS Society and International MPS Network launched its third #FlyforMPS digital campaign aimed to increase awareness about.
• Treatment Insights
• Based on treatment type, the market is categorized into enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and others. In 2018, the ERT segment accounted for the largest market share and is anticipated to hold onto its dominance over the forecast period. This is attributed to improved sales of Shire Plc’s ELAPRASE and potential for worldwide approval of GC Pharma’s product called Hunterase.
• Shire Plc’s Elaprase (idursulfase) is the single major drug used for the treatment of Hunter syndrome, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea as of now. These drugs have addressed a significant unmet need. However, the high cost of these drugs is expected to be a major factor hindering their market growth. For instance, Idursulfase (Elaprase) drug costs around USD 3,100 per 6mg/3ml vial.
• Regional Insights
• In 2018, North America dominated the market owing to favorable regulations for orphan drug development, rising awareness among people concerning rare diseases, increased funding for research activities and improved healthcare facilities. Furthermore, the favorable reimbursement policies for expensive drugs such as ELAPRASE in the U.S. have supported its adoption and fueled the regional growth.
• Asia Pacific region is projected to exhibit a lucrative growth rate over the forecast period. Japan, China, and India are expected to emerge as potential countries for growth, owing to their high unmet needs in the market. Major players are focused on gaining approval for their novel therapies and are penetrating these markets to attain a major share. For instance, in July 2019, CANbridge Pharmaceuticals Inc. filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its novel treatment drug called Hunterase in China. Hunterase (idursulfase beta) is a patented therapy of GC Pharma indicated for the treatment of Hunter syndrome.
• KEY MARKET SEGMENTS
• By Treatment
• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplant (HSCT)
• Others
• By Region
• North America
• Europe
• Asia Pacific
• MEA
• KEY PLAYERS
• Shire Plc. (Takeda Pharmaceutical Company)
• GC Pharma
• JCR Pharmaceuticals Co Ltd.
• RegenxBio Inc.
• Sangamo Therapeutics, Inc.
• ArmaGen Inc
• Inventiva S.A.
• Denali Therapeutics Inc.
• Bioasis Technologies Inc.
• Esteve